49 related articles for article (PubMed ID: 20339946)
21. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.
Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
[TBL] [Abstract][Full Text] [Related]
23. The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer.
Hisamatsu T; Mabuchi S; Sasano T; Kuroda H; Takahashi R; Matsumoto Y; Kawano M; Kozasa K; Takahashi K; Sawada K; Matsuo K; Tamada Y; Morii E; Kitadai Y; Kimura T
Clin Exp Metastasis; 2015 Dec; 32(8):789-98. PubMed ID: 26443563
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma.
Lu J; Pan Y; Xia X; Gu Y; Lei Y
Biomed Res Int; 2015; 2015():417210. PubMed ID: 26357655
[TBL] [Abstract][Full Text] [Related]
25. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells.
Zhang D; Xiang J; Gu Y; Xu W; Xu H; Zu M; Pei D; Zheng J
Oncol Lett; 2014 Aug; 8(2):575-581. PubMed ID: 25009644
[TBL] [Abstract][Full Text] [Related]
27. Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.
Fountzilas E; Kotoula V; Angouridakis N; Karasmanis I; Wirtz RM; Eleftheraki AG; Veltrup E; Markou K; Nikolaou A; Pectasides D; Fountzilas G
PLoS One; 2013; 8(8):e70429. PubMed ID: 23950933
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
29. Targeted treatments for metastatic esophageal squamous cell cancer.
Digklia A; Voutsadakis IA
World J Gastrointest Oncol; 2013 May; 5(5):88-96. PubMed ID: 23799158
[TBL] [Abstract][Full Text] [Related]
30. A comparison between manual and automated evaluations of tissue microarray patterns of protein expression.
Alvarenga AW; Coutinho-Camillo CM; Rodrigues BR; Rocha RM; Torres LF; Martins VR; da Cunha IW; Hajj GN
J Histochem Cytochem; 2013 Apr; 61(4):272-82. PubMed ID: 23340270
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.
Li M; Sun H; Song L; Gao X; Chang W; Qin X
Oncol Lett; 2012 Dec; 4(6):1213-1218. PubMed ID: 23205120
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for esophagogastric cancers: a review.
Khattak MA; Martin HL; Karapetis CS
Onco Targets Ther; 2012; 5():91-102. PubMed ID: 22719211
[TBL] [Abstract][Full Text] [Related]
33. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
[TBL] [Abstract][Full Text] [Related]
34. High expression of phosphorylated 4E-binding protein 1 is an adverse prognostic factor in esophageal squamous cell carcinoma.
Yeh CJ; Chuang WY; Chao YK; Liu YH; Chang YS; Kuo SY; Tseng CK; Chang HK; Hsueh C
Virchows Arch; 2011 Feb; 458(2):171-8. PubMed ID: 21046149
[TBL] [Abstract][Full Text] [Related]
35. Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima R; Sato N; Imamura Y; Hiyoshi Y; Nagai Y; Hayashi N; Iyama K; Baba H
Ann Surg Oncol; 2010 Sep; 17(9):2486-93. PubMed ID: 20339946
[TBL] [Abstract][Full Text] [Related]
36. mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy?
Boone J; Ten Kate FJ; Offerhaus GJ; van Diest PJ; Rinkes IH; van Hillegersberg R
J Clin Pathol; 2008 Aug; 61(8):909-13. PubMed ID: 18474542
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma.
Takeno S; Noguchi T; Kikuchi R; Uchida Y; Yokoyama S; Müller W
Cancer; 2002 Jun; 94(11):2874-81. PubMed ID: 12115375
[TBL] [Abstract][Full Text] [Related]
39. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
